Maternal measles antibody decay in rural Bangladeshi infants - Implications for vaccination schedules

Vaccine

Volumn 16, Issue 6, 1998, Pages 564-568

  De Francisco, A ^a,b,c   Hall, A J ^b   Unicomb, L ^a   Chakraborty, J ^a   Yunus, Md ^a   Sack, R B ^c  

^a ICDDRB Public Health Sciences Division   (Bangladesh)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antibody decay; ELISA; Maternal antibody; Measles; PRN; Vaccination

Indexed keywords

MATERNAL ANTIBODY; MEASLES ANTIBODY; MEASLES VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BANGLADESH; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MATERNAL AGE; MEASLES; MEASLES VACCINATION; MULTIPLE REGRESSION; PARITY; PLAQUE FORMING CELL; PRIORITY JOURNAL; RISK FACTOR; RURAL POPULATION; SEROCONVERSION;

ADULT; ANTIBODIES, VIRAL; BANGLADESH; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FETAL BLOOD; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION SCHEDULE; INFANT; MALE; MEASLES; MEASLES VACCINE; NEUTRALIZATION TESTS;

EID: 0032054509     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00245-4     Document Type: Article

References (11)

1. 1 Isomura, S. Community-based epidemiological studies on measles in Karachi, Pakistan. Microbiol. Immunol. 1994, 38, (3), 165-169.
2. 2 Fauveau, V., Chakraborty, J., Sarder, A.M., Khan, M.A. and Koenig, M.A. Measles among under-9-month-old in rural Bangladesh: its significance for age at immunization. Bull. WHO 1991, 69, (1), 67-72.
3. 3 de Francisco, A., Fauveau, V., Sarder, A.M., Chowdhury, H.R., Chakraborty, J. and Yunus, M. Measles in rural Bangladesh: issues of validation and age distribution. Int. J. Epidemiol. 1994, 23, (2), 393-399.
4. 4 Binnendijik, R.S., Poelen, M.C., Amerongen, G., Vries, P. and Osterhaus, A.D.M. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 1997, 175, 524-532.
5. 5 Chen, R.T., Markowitz, L.E. and Albrecht. P. et al. Measles antibody: reevaluation of protective titres. J. Infect. Dis. 1990, 162, (5), 1036-1042.
6. 6 Samb, B., Aaby, P. and Whittle, H.C. et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. PID 1995, 14, (3), 203-209.
7. 7 Collaborative study by the Ministry of Kenya and the WHO. Measles immunity in the first year of life and the optimum age for vaccination in Kenyan children. Bull. WHO 1977, 55, 21-31
8. 8 National Vaccine Advisory Committee. The measles epidemic: the problems, barriers and recommendations. JAMA 1991, 266, 1547-1552.
9. 9 Whittle, H.C., Rowland, M.G.M., Mann, G.F., Lamb, W.H. and Lewis, R.A. Immunisation of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine. Lancet 1984, 2, 834-847.
10. 10 Lennon, J.L. and Black, F.L. Maternally derived measles immunity in era of vaccine-protected mothers. J. Pediatr. 1986, May, 671-676
11. 11 de Serres, G., Joly, J.R., Fauvel, M., Meyer, F., Masse, B. and Boulianne, N. Passive immunity against measles during the first 8 months of life of infants born to vaccinated mothers or to mothers who sustained measles. Vaccine 1997, 15, (6/7), 620-623.